<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37080828</PMID><DateCompleted><Year>2023</Year><Month>05</Month><Day>12</Day></DateCompleted><DateRevised><Year>2023</Year><Month>05</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1879-3061</ISSN><JournalIssue CitedMedium="Internet"><Volume>34</Volume><Issue>6</Issue><PubDate><Year>2023</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Trends in endocrinology and metabolism: TEM</Title><ISOAbbreviation>Trends Endocrinol Metab</ISOAbbreviation></Journal><ArticleTitle>Long COVID: pathophysiological factors and abnormalities of coagulation.</ArticleTitle><Pagination><StartPage>321</StartPage><EndPage>344</EndPage><MedlinePgn>321-344</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.tem.2023.03.002</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1043-2760(23)00055-3</ELocationID><Abstract><AbstractText>Acute COVID-19 infection is followed by prolonged symptoms in approximately one in ten cases: known as Long COVID. The disease affects ~65 million individuals worldwide. Many pathophysiological processes appear to underlie Long COVID, including viral factors (persistence, reactivation, and bacteriophagic action of SARS CoV-2); host factors (chronic inflammation, metabolic and endocrine dysregulation, immune dysregulation, and autoimmunity); and downstream impacts (tissue damage from the initial infection, tissue hypoxia, host dysbiosis, and autonomic nervous system dysfunction). These mechanisms culminate in the long-term persistence of the disorder characterized by a thrombotic endothelialitis, endothelial inflammation, hyperactivated platelets, and fibrinaloid microclots. These abnormalities of blood vessels and coagulation affect every organ system and represent a unifying pathway for the various symptoms of Long COVID.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 The Author(s). Published by Elsevier Ltd.. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Turner</LastName><ForeName>Simone</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Physiological Sciences, Faculty of Science, Stellenbosch University, Stellenbosch, Private Bag X1, Matieland, 7602, South Africa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khan</LastName><ForeName>M Asad</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>North West Lung Centre, Manchester University Hospitals, Manchester, M23 9LT, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Putrino</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Rehabilitation and Human Performance, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Woodcock</LastName><ForeName>Ashley</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>The University of Manchester, Oxford Road, Manchester, M13 9PL, UK; Manchester Academic Health Science Centre, CityLabs, Manchester, M13 9NQ, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kell</LastName><ForeName>Douglas B</ForeName><Initials>DB</Initials><AffiliationInfo><Affiliation>Department of Physiological Sciences, Faculty of Science, Stellenbosch University, Stellenbosch, Private Bag X1, Matieland, 7602, South Africa; Department of Biochemistry and Systems Biology, Institute of Systems, Molecular and Integrative Biology, Faculty of Health and Life Sciences, University of Liverpool, Crown St, Liverpool, L69 7ZB, UK; The Novo Nordisk Foundation Centre for Biosustainability, Building 220, Kemitorvet, Technical University of Denmark, 2800 Kongens Lyngby, Denmark. Electronic address: dbk@liv.ac.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pretorius</LastName><ForeName>Etheresia</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Physiological Sciences, Faculty of Science, Stellenbosch University, Stellenbosch, Private Bag X1, Matieland, 7602, South Africa; Department of Biochemistry and Systems Biology, Institute of Systems, Molecular and Integrative Biology, Faculty of Health and Life Sciences, University of Liverpool, Crown St, Liverpool, L69 7ZB, UK. Electronic address: resiap@sun.ac.za.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>04</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Trends Endocrinol Metab</MedlineTA><NlmUniqueID>9001516</NlmUniqueID><ISSNLinking>1043-2760</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013927" MajorTopicYN="Y">Thrombosis</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">cardiovascular outcomes</Keyword><Keyword MajorTopicYN="N">clotting pathology</Keyword><Keyword MajorTopicYN="N">endothelialitis</Keyword><Keyword MajorTopicYN="N">long COVID</Keyword></KeywordList><CoiStatement>Declaration of interests None are declared by the authors.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>1</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>3</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>3</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>5</Month><Day>12</Day><Hour>7</Hour><Minute>6</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>4</Month><Day>21</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>4</Month><Day>20</Day><Hour>21</Hour><Minute>59</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>4</Month><Day>19</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37080828</ArticleId><ArticleId IdType="pmc">PMC10113134</ArticleId><ArticleId IdType="doi">10.1016/j.tem.2023.03.002</ArticleId><ArticleId IdType="pii">S1043-2760(23)00055-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Pretorius E., et al. Persistent clotting protein pathology in Long COVID/Post-Acute Sequelae of COVID-19 (PASC) is accompanied by increased levels of antiplasmin. Cardiovasc. Diabetol. 2021;20:172.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8381139</ArticleId><ArticleId IdType="pubmed">34425843</ArticleId></ArticleIdList></Reference><Reference><Citation>Cascella M., et al. StatPearls Publishing; 2022. Features, Evaluation, and Treatment of Coronavirus (COVID-19)</Citation><ArticleIdList><ArticleId IdType="pubmed">32150360</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiersinga W.J., et al. Pathophysiology, transmission, diagnosis, and treatment of Coronavirus disease 2019 (COVID-19): a review. JAMA. 2020;324:782&#x2013;793.</Citation><ArticleIdList><ArticleId IdType="pubmed">32648899</ArticleId></ArticleIdList></Reference><Reference><Citation>Raveendran A.V. Long COVID-19: challenges in the diagnosis and proposed diagnostic criteria. Diabetes Metab. Syndr. 2021;15:145&#x2013;146.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7737559</ArticleId><ArticleId IdType="pubmed">33341598</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballering A.V., et al. Persistence of somatic symptoms after COVID-19 in the Netherlands: an observational cohort study. Lancet. 2022;400:452&#x2013;461.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9352274</ArticleId><ArticleId IdType="pubmed">35934007</ArticleId></ArticleIdList></Reference><Reference><Citation>Callard F., Perego E. How and why patients made Long Covid. Soc. Sci. Med. 2021;268</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7539940</ArticleId><ArticleId IdType="pubmed">33199035</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenhalgh T., et al. Management of post-acute covid-19 in primary care. BMJ. 2020;370</Citation><ArticleIdList><ArticleId IdType="pubmed">32784198</ArticleId></ArticleIdList></Reference><Reference><Citation>Pretorius E., et al. Prevalence of symptoms, comorbidities, fibrin amyloid microclots and platelet pathology in individuals with Long COVID/Post-Acute Sequelae of COVID-19 (PASC) Cardiovasc. Diabetol. 2022;21:148.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9356426</ArticleId><ArticleId IdType="pubmed">35933347</ArticleId></ArticleIdList></Reference><Reference><Citation>Seessle J., et al. Persistent symptoms in adult patients 1 year after Coronavirus disease 2019 (COVID-19): a prospective cohort study. Clin. Infect. Dis. 2022;74:1191&#x2013;1198.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8394862</ArticleId><ArticleId IdType="pubmed">34223884</ArticleId></ArticleIdList></Reference><Reference><Citation>Grobbelaar L.M., et al. SARS-CoV-2 spike protein S1 induces fibrin(ogen) resistant to fibrinolysis: implications for microclot formation in COVID-19. Biosci. Rep. 2021;41</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8380922</ArticleId><ArticleId IdType="pubmed">34328172</ArticleId></ArticleIdList></Reference><Reference><Citation>Kell D.B., et al. A central role for amyloid fibrin microclots in long COVID/PASC: origins and therapeutic implications. Biochem. J. 2022;479:537&#x2013;559.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8883497</ArticleId><ArticleId IdType="pubmed">35195253</ArticleId></ArticleIdList></Reference><Reference><Citation>Kruger A., et al. Proteomics of fibrin amyloid microclots in long COVID/post-acute sequelae of COVID-19 (PASC) shows many entrapped pro-inflammatory molecules that may also contribute to a failed fibrinolytic system. Cardiovasc. Diabetol. 2022;21:190.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9491257</ArticleId><ArticleId IdType="pubmed">36131342</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis H.E., et al. Long COVID: major findings, mechanisms and recommendations. Nat. Rev. Microbiol. 2023;21:133&#x2013;146.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9839201</ArticleId><ArticleId IdType="pubmed">36639608</ArticleId></ArticleIdList></Reference><Reference><Citation>Cutler D.M., Summers L.H. The COVID-19 pandemic and the $16 trillion virus. JAMA. 2020;324:1495&#x2013;1496.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7604733</ArticleId><ArticleId IdType="pubmed">33044484</ArticleId></ArticleIdList></Reference><Reference><Citation>Carf&#xec; A., et al. Persistent symptoms in patients after acute COVID-19. JAMA. 2020;324:603&#x2013;605.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7349096</ArticleId><ArticleId IdType="pubmed">32644129</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C., et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet. 2021;397:220&#x2013;232.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7833295</ArticleId><ArticleId IdType="pubmed">33428867</ArticleId></ArticleIdList></Reference><Reference><Citation>Twomey R., et al. Chronic fatigue and postexertional malaise in people living with long COVID: an observational study. Phys. Ther. 2022;102</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9383197</ArticleId><ArticleId IdType="pubmed">35079817</ArticleId></ArticleIdList></Reference><Reference><Citation>Haffke M., et al. Endothelial dysfunction and altered endothelial biomarkers in patients with post-COVID-19 syndrome and chronic fatigue syndrome (ME/CFS) J. Transl. Med. 2022;20:138.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8938726</ArticleId><ArticleId IdType="pubmed">35317812</ArticleId></ArticleIdList></Reference><Reference><Citation>Mancini D.M., et al. Use of cardiopulmonary stress testing for patients with unexplained dyspnea post-Coronavirus disease. JACC Heart Fail. 2021;9:927&#x2013;937.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8629098</ArticleId><ArticleId IdType="pubmed">34857177</ArticleId></ArticleIdList></Reference><Reference><Citation>Komaroff A.L., Bateman L. Will COVID-19 lead to myalgic encephalomyelitis/chronic fatigue syndrome? Front. Med. (Lausanne) 2020;7</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7848220</ArticleId><ArticleId IdType="pubmed">33537329</ArticleId></ArticleIdList></Reference><Reference><Citation>Morrow A.K., et al. Long-term COVID 19 sequelae in adolescents: the overlap with orthostatic intolerance and ME/CFS. Curr. Pediatr. Rep. 2022;10:31&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8906524</ArticleId><ArticleId IdType="pubmed">35287333</ArticleId></ArticleIdList></Reference><Reference><Citation>Sorensen A.I.V., et al. A nationwide questionnaire study of post-acute symptoms and health problems after SARS-CoV-2 infection in Denmark. Nat. Commun. 2022;13:4213.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9302226</ArticleId><ArticleId IdType="pubmed">35864108</ArticleId></ArticleIdList></Reference><Reference><Citation>Berg S.K., et al. Long COVID symptoms in SARS-CoV-2-positive children aged 0&#x2013;14 years and matched controls in Denmark (LongCOVIDKidsDK): a national, cross-sectional study. Lancet Child Adolesc. Health. 2022;6:614&#x2013;623.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9221683</ArticleId><ArticleId IdType="pubmed">35752194</ArticleId></ArticleIdList></Reference><Reference><Citation>Morand A., et al. Similar patterns of [(18)F]-FDG brain PET hypometabolism in paediatric and adult patients with long COVID: a paediatric case series. Eur. J. Nucl. Med. Mol. Imaging. 2022;49:913&#x2013;920.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8376118</ArticleId><ArticleId IdType="pubmed">34414470</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper S., et al. Long COVID-19 liver manifestation in children. J. Pediatr. Gastroenterol. Nutr. 2022;75:244&#x2013;251.</Citation><ArticleIdList><ArticleId IdType="pubmed">35687535</ArticleId></ArticleIdList></Reference><Reference><Citation>Menni C., et al. Real-time tracking of self-reported symptoms to predict potential COVID-19. Nat. Med. 2020;26:1037&#x2013;1040.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7751267</ArticleId><ArticleId IdType="pubmed">32393804</ArticleId></ArticleIdList></Reference><Reference><Citation>Asadi-Pooya A.A., et al. Risk factors associated with Long COVID syndrome: a retrospective study. Iran J. Med. Sci. 2021;46:428&#x2013;436.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8611223</ArticleId><ArticleId IdType="pubmed">34840383</ArticleId></ArticleIdList></Reference><Reference><Citation>Sudre C.H., et al. Attributes and predictors of long COVID. Nat. Med. 2021;27:626&#x2013;631.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7611399</ArticleId><ArticleId IdType="pubmed">33692530</ArticleId></ArticleIdList></Reference><Reference><Citation>Raveendran A.V., et al. Long COVID: an overview. Diabetes Metab. Syndr. 2021;15:869&#x2013;875.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8056514</ArticleId><ArticleId IdType="pubmed">33892403</ArticleId></ArticleIdList></Reference><Reference><Citation>Tenforde M.W., et al. Symptom duration and risk factors for delayed return to usual health among outpatients with COVID-19 in a multistate health care systems network - United States, March-June 2020. MMWR Morb. Mortal. Wkly Rep. 2020;69:993&#x2013;998.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7392393</ArticleId><ArticleId IdType="pubmed">32730238</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang B., et al. Sex-based clinical and immunological differences in COVID-19. BMC Infect. Dis. 2021;21:647.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8256650</ArticleId><ArticleId IdType="pubmed">34225644</ArticleId></ArticleIdList></Reference><Reference><Citation>Ziauddeen N., et al. Characteristics and impact of Long Covid: findings from an online survey. PLoS ONE. 2022;17</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8903286</ArticleId><ArticleId IdType="pubmed">35259179</ArticleId></ArticleIdList></Reference><Reference><Citation>Williamson A.E., et al. Short-term and long-term impacts of COVID-19 on economic vulnerability: a population-based longitudinal study (COVIDENCE UK) BMJ Open. 2022;12</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9402446</ArticleId><ArticleId IdType="pubmed">35998959</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis H.E., et al. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine. 2021;38</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8280690</ArticleId><ArticleId IdType="pubmed">34308300</ArticleId></ArticleIdList></Reference><Reference><Citation>Stussman B., et al. Characterization of post-exertional malaise in patients with myalgic encephalomyelitis/chronic fatigue syndrome. Front. Neurol. 2020;11:1025.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7530890</ArticleId><ArticleId IdType="pubmed">33071931</ArticleId></ArticleIdList></Reference><Reference><Citation>Wright J., et al. The relationship between physical activity and Long COVID: a cross-sectional study. Int. J. Environ. Res. Public Health. 2022;19:5093.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9105041</ArticleId><ArticleId IdType="pubmed">35564488</ArticleId></ArticleIdList></Reference><Reference><Citation>Blitshteyn S., et al. Multi-disciplinary collaborative consensus guidance statement on the assessment and treatment of autonomic dysfunction in patients with post-acute sequelae of SARS-CoV-2 infection (PASC) PM R. 2022;14:1270&#x2013;1291.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9538426</ArticleId><ArticleId IdType="pubmed">36169154</ArticleId></ArticleIdList></Reference><Reference><Citation>Soriano J.B., et al. A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect. Dis. 2022;22:e102&#x2013;e107.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8691845</ArticleId><ArticleId IdType="pubmed">34951953</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso M.J., et al. Chronic viral coinfections differentially affect the likelihood of developing long COVID. J. Clin. Invest. 2023;133</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9888380</ArticleId><ArticleId IdType="pubmed">36454631</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Y., et al. Multiple early factors anticipate post-acute COVID-19 sequelae. Cell. 2022;185:881&#x2013;895.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8786632</ArticleId><ArticleId IdType="pubmed">35216672</ArticleId></ArticleIdList></Reference><Reference><Citation>Notarte K.I., et al. Impact of COVID-19 vaccination on the risk of developing long-COVID and on existing long-COVID symptoms: a systematic review. eClinicalMedicine. 2022;53</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9417563</ArticleId><ArticleId IdType="pubmed">36051247</ArticleId></ArticleIdList></Reference><Reference><Citation>Taquet M., et al. Six-month sequelae of post-vaccination SARS-CoV-2 infection: a retrospective cohort study of 10,024 breakthrough infections. Brain Behav. Immun. 2022;103:154&#x2013;162.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9013695</ArticleId><ArticleId IdType="pubmed">35447302</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsuchida T., et al. Relationship between changes in symptoms and antibody titers after a single vaccination in patients with Long COVID. J. Med. Virol. 2022;94:3416&#x2013;3420.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9088489</ArticleId><ArticleId IdType="pubmed">35238053</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayoubkhani D., Bosworth M. Office for National Statistics; 2022. Self-Reported Long COVID after Infection with the Omicron Variant in the UK.</Citation></Reference><Reference><Citation>Frontera J.A., et al. Neurological events reported after COVID-19 vaccines: an analysis of VAERS. Ann. Neurol. 2022;91:756&#x2013;771.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9082459</ArticleId><ArticleId IdType="pubmed">35233819</ArticleId></ArticleIdList></Reference><Reference><Citation>Potgieter M., et al. The dormant blood microbiome in chronic, inflammatory diseases. FEMS Microbiol. Rev. 2015;39:567&#x2013;591.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4487407</ArticleId><ArticleId IdType="pubmed">25940667</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacobs J.J.L. Persistent SARS-2 infections contribute to long COVID-19. Med. Hypotheses. 2021;149</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7884250</ArticleId><ArticleId IdType="pubmed">33621843</ArticleId></ArticleIdList></Reference><Reference><Citation>Griffin D.A.-O. Why does viral RNA sometimes persist after recovery from acute infections? PLoS Biol. 2022;20</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9191737</ArticleId><ArticleId IdType="pubmed">35648781</ArticleId></ArticleIdList></Reference><Reference><Citation>Proal A.D., VanElzakker M.B. Long COVID or post-acute sequelae of COVID-19 (PASC): an overview of biological factors that may contribute to persistent symptoms. Front. Microbiol. 2021;12</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8260991</ArticleId><ArticleId IdType="pubmed">34248921</ArticleId></ArticleIdList></Reference><Reference><Citation>Mantovani A., et al. Long Covid: where we stand and challenges ahead. Cell Death Differ. 2022;29:1891&#x2013;1900.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9449925</ArticleId><ArticleId IdType="pubmed">36071155</ArticleId></ArticleIdList></Reference><Reference><Citation>Desimmie B.A., et al. Insights into SARS-CoV-2 persistence and its relevance. Viruses. 2021;13:1025.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8228265</ArticleId><ArticleId IdType="pubmed">34072390</ArticleId></ArticleIdList></Reference><Reference><Citation>Rouse B.T., Sehrawat S. Immunity and immunopathology to viruses: what decides the outcome? Nat. Rev. Immunol. 2010;10:514&#x2013;526.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3899649</ArticleId><ArticleId IdType="pubmed">20577268</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinho J.R.R., et al. Long term persistence of coronavirus SARS-CoV-2 infection. Einstein (Sao Paulo) 2021;19</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8664288</ArticleId><ArticleId IdType="pubmed">34909977</ArticleId></ArticleIdList></Reference><Reference><Citation>Marx V. Scientists set out to connect the dots on long COVID. Nat. Methods. 2021;18:449&#x2013;453.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8081406</ArticleId><ArticleId IdType="pubmed">33911230</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoang V.T., et al. Recurrence of positive SARS-CoV-2 in patients recovered from COVID-19. J. Med. Virol. 2020;92:2366&#x2013;2367.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7280660</ArticleId><ArticleId IdType="pubmed">32449789</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalkeri R., et al. SARS-CoV-2 shedding from asymptomatic patients: contribution of potential extrapulmonary tissue reservoirs. Am. J. Trop. Med. Hyg. 2020;103:18&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7356473</ArticleId><ArticleId IdType="pubmed">32406369</ArticleId></ArticleIdList></Reference><Reference><Citation>Xing Y.H., et al. Prolonged viral shedding in feces of pediatric patients with Coronavirus disease 2019. J. Microbiol. Immunol. Infect. 2020;53:473&#x2013;480.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7141453</ArticleId><ArticleId IdType="pubmed">32276848</ArticleId></ArticleIdList></Reference><Reference><Citation>Bergmann C.C., Silverman R.H. COVID-19: coronavirus replication, pathogenesis, and therapeutic strategies. Cleve. Clin. J. Med. 2020;87:321&#x2013;327.</Citation><ArticleIdList><ArticleId IdType="pubmed">32366502</ArticleId></ArticleIdList></Reference><Reference><Citation>Suprewicz &#x141;., et al. Extracellular vimentin as a target against SARS-CoV-2 host cell invasion. Small. 2022;18</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9252327</ArticleId><ArticleId IdType="pubmed">34866333</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawase M., et al. Biochemical analysis of coronavirus spike glycoprotein conformational intermediates during membrane fusion. J. Virol. 2019;93</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6744234</ArticleId><ArticleId IdType="pubmed">31315988</ArticleId></ArticleIdList></Reference><Reference><Citation>Walls A.C., et al. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell. 2020;181:281&#x2013;292.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7102599</ArticleId><ArticleId IdType="pubmed">32155444</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang C., et al. Protein structure and sequence reanalysis of 2019-nCoV genome refutes snakes as its intermediate host and the unique similarity between its spike protein insertions and HIV-1. J. Proteome Res. 2020;19:1351&#x2013;1360.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7099673</ArticleId><ArticleId IdType="pubmed">32200634</ArticleId></ArticleIdList></Reference><Reference><Citation>Watanabe Y., et al. Site-specific glycan analysis of the SARS-CoV-2 spike. Science. 2020;369:330&#x2013;333.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7199903</ArticleId><ArticleId IdType="pubmed">32366695</ArticleId></ArticleIdList></Reference><Reference><Citation>Flores-Alanis A., et al. The receptor binding domain of SARS-CoV-2 spike protein is the result of an ancestral recombination between the bat-CoV RaTG13 and the pangolin-CoV MP789. BMC Res. Notes. 2020;13:398.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7450963</ArticleId><ArticleId IdType="pubmed">32854762</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer B., et al. Characterising proteolysis during SARS-CoV-2 infection identifies viral cleavage sites and cellular targets with therapeutic potential. Nat. Commun. 2021;12:5553.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8455558</ArticleId><ArticleId IdType="pubmed">34548480</ArticleId></ArticleIdList></Reference><Reference><Citation>Karn V., et al. Extracellular vesicle-based therapy for COVID-19: promises, challenges and future prospects. Biomedicines. 2021;9:1373.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8533559</ArticleId><ArticleId IdType="pubmed">34680490</ArticleId></ArticleIdList></Reference><Reference><Citation>Borowiec B.M., et al. Small extracellular vesicles and COVID19-using the &#x2018;Trojan Horse&#x2019; to tackle the giant. Cells. 2021;10:3383.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8699232</ArticleId><ArticleId IdType="pubmed">34943891</ArticleId></ArticleIdList></Reference><Reference><Citation>Barberis E., et al. Circulating exosomes are strongly involved in SARS-CoV-2 infection. Front. Mol. Biosci. 2021;8</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7937875</ArticleId><ArticleId IdType="pubmed">33693030</ArticleId></ArticleIdList></Reference><Reference><Citation>Eymieux S., et al. Secretory vesicles are the principal means of SARS-CoV-2 egress. Cells. 2021;10:2047.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8393858</ArticleId><ArticleId IdType="pubmed">34440816</ArticleId></ArticleIdList></Reference><Reference><Citation>Kell D.B., Pretorius E. No effects without causes: the Iron Dysregulation and Dormant Microbes hypothesis for chronic, inflammatory diseases. Biol. Rev. Camb. Philos. Soc. 2018;93:1518&#x2013;1557.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6055827</ArticleId><ArticleId IdType="pubmed">29575574</ArticleId></ArticleIdList></Reference><Reference><Citation>Rebman A.W., Aucott J.N. Post-treatment Lyme Disease as a model for persistent symptoms in Lyme Disease. Front. Med. (Lausanne) 2020;7:57.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7052487</ArticleId><ArticleId IdType="pubmed">32161761</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumata R., et al. A tissue level atlas of the healthy human virome. BMC Biol. 2020;18:55.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7269688</ArticleId><ArticleId IdType="pubmed">32493363</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen C., et al. Risk surveillance and mitigation: autoantibodies as triggers and inhibitors of severe reactions to SARS-CoV-2 infection. Mol. Med. 2021;27:160.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8686808</ArticleId><ArticleId IdType="pubmed">34930107</ArticleId></ArticleIdList></Reference><Reference><Citation>Brogna C., et al. Could SARS-CoV-2 have bacteriophage behavior or induce the activity of other bacteriophages? Vaccines (Basel) 2022;10:708.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9143435</ArticleId><ArticleId IdType="pubmed">35632464</ArticleId></ArticleIdList></Reference><Reference><Citation>Patterson B.K., et al. Immune-based prediction of COVID-19 severity and chronicity decoded using machine learning. Front. Immunol. 2021;12</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8273732</ArticleId><ArticleId IdType="pubmed">34262570</ArticleId></ArticleIdList></Reference><Reference><Citation>Scaglioni V., Soriano E.R. Are superantigens the cause of cytokine storm and viral sepsis in severe COVID-19? Observations and hypothesis. Scand. J. Immunol. 2020;92</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7404497</ArticleId><ArticleId IdType="pubmed">32697367</ArticleId></ArticleIdList></Reference><Reference><Citation>Kell D.B., Pretorius E. To what extent are the terminal stages of sepsis, septic shock, systemic inflammatory response syndrome, and multiple organ dysfunction syndrome actually driven by a prion/amyloid form of fibrin? Semin. Thromb. Hemost. 2017;44:224&#x2013;238.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6193370</ArticleId><ArticleId IdType="pubmed">28778104</ArticleId></ArticleIdList></Reference><Reference><Citation>Tavakolpour S., et al. Lymphopenia during the COVID-19 infection: what it shows and what can be learned. Immunol. Lett. 2020;225:31&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7305732</ArticleId><ArticleId IdType="pubmed">32569607</ArticleId></ArticleIdList></Reference><Reference><Citation>Fathi N., Rezaei N. Lymphopenia in COVID-19: therapeutic opportunities. Cell Biol. Int. 2020;44:1792&#x2013;1797.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7283672</ArticleId><ArticleId IdType="pubmed">32458561</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng Y., et al. Dynamic changes of lymphocyte counts in adult patients with severe pandemic H1N1 influenza A. J. Infect. Public Health. 2019;12:878&#x2013;883.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7102863</ArticleId><ArticleId IdType="pubmed">31202719</ArticleId></ArticleIdList></Reference><Reference><Citation>Kong M., et al. Higher level of neutrophil-to-lymphocyte is associated with severe COVID-19. Epidemiol. Infect. 2020;148</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7360950</ArticleId><ArticleId IdType="pubmed">32641174</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu F., et al. A compromised specific humoral immune response against the SARS-CoV-2 receptor-binding domain is related to viral persistence and periodic shedding in the gastrointestinal tract. Cell. Mol. Immunol. 2020;17:1119&#x2013;1125.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7546387</ArticleId><ArticleId IdType="pubmed">33037400</ArticleId></ArticleIdList></Reference><Reference><Citation>Ercolini A.M., Miller S.D. The role of infections in autoimmune disease. Clin. Exp. Immunol. 2009;155:1&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2665673</ArticleId><ArticleId IdType="pubmed">19076824</ArticleId></ArticleIdList></Reference><Reference><Citation>Eizirik D.L., Op de Beeck A. Coxsackievirus and Type 1 diabetes mellitus: the wolf's footprints. Trends Endocrinol. Metab. 2018;29:137&#x2013;139.</Citation><ArticleIdList><ArticleId IdType="pubmed">29326001</ArticleId></ArticleIdList></Reference><Reference><Citation>Hober D., et al. Immunology in the clinic review series; focus on type 1 diabetes and viruses: role of antibodies enhancing the infection with Coxsackievirus-B in the pathogenesis of type 1 diabetes. Clin. Exp. Immunol. 2012;168:47&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3390492</ArticleId><ArticleId IdType="pubmed">22385236</ArticleId></ArticleIdList></Reference><Reference><Citation>Stolzel U., et al. Autoimmunity and HCV infection in porphyria cutanea tarda: a controlled study. Cell Mol. Biol. (Noisy-le-grand) 2002;48:43&#x2013;47.</Citation><ArticleIdList><ArticleId IdType="pubmed">11929046</ArticleId></ArticleIdList></Reference><Reference><Citation>Ebringer A., et al. Rheumatoid arthritis, Proteus, anti-CCP antibodies and Karl Popper. Autoimmun. Rev. 2010;9:216&#x2013;223.</Citation><ArticleIdList><ArticleId IdType="pubmed">19895906</ArticleId></ArticleIdList></Reference><Reference><Citation>Pretorius E., et al. Major involvement of bacterial components in rheumatoid arthritis and its accompanying oxidative stress, systemic inflammation and hypercoagulability. Exp. Biol. Med. (Maywood) 2017;242:355&#x2013;373.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5298544</ArticleId><ArticleId IdType="pubmed">27889698</ArticleId></ArticleIdList></Reference><Reference><Citation>Kell D.B., Kenny L.C. A dormant microbial component in the development of preeclampsia. Front. Med. (Lausanne) 2016;3:60.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5126693</ArticleId><ArticleId IdType="pubmed">27965958</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y., et al. Clinical and autoimmune characteristics of severe and critical cases of COVID-19. Clin. Transl. Sci. 2020;13:1077&#x2013;1086.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7264560</ArticleId><ArticleId IdType="pubmed">32315487</ArticleId></ArticleIdList></Reference><Reference><Citation>Bastard P., et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science. 2020;370</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7857397</ArticleId><ArticleId IdType="pubmed">32972996</ArticleId></ArticleIdList></Reference><Reference><Citation>Vlachoyiannopoulos P.G., et al. Autoantibodies related to systemic autoimmune rheumatic diseases in severely ill patients with COVID-19. Ann. Rheum. Dis. 2020;79:1661&#x2013;1663.</Citation><ArticleIdList><ArticleId IdType="pubmed">32581086</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao Z.W., et al. Autoantibodies in COVID-19: frequency and function. Autoimmun. Rev. 2021;20</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7813482</ArticleId><ArticleId IdType="pubmed">33476817</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallukat G., et al. Functional autoantibodies against G-protein coupled receptors in patients with persistent Long-COVID-19 symptoms. J. Transl. Autoimmun. 2021;4</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8049853</ArticleId><ArticleId IdType="pubmed">33880442</ArticleId></ArticleIdList></Reference><Reference><Citation>Cabral-Marques O., et al. Autoantibodies targeting GPCRs and RAS-related molecules associate with COVID-19 severity. Nat. Commun. 2022;13:1220.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8907309</ArticleId><ArticleId IdType="pubmed">35264564</ArticleId></ArticleIdList></Reference><Reference><Citation>Szewczykowski C., et al. Long COVID: association of functional autoantibodies against G-protein-coupled receptors with an impaired retinal microcirculation. Int. J. Mol. Sci. 2022;23:7209.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9266742</ArticleId><ArticleId IdType="pubmed">35806214</ArticleId></ArticleIdList></Reference><Reference><Citation>Hohberger B., et al. Case report: neutralization of autoantibodies targeting G-protein-coupled receptors improves capillary impairment and fatigue symptoms after COVID-19 infection. Front. Med. (Lausanne) 2021;8</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8637609</ArticleId><ArticleId IdType="pubmed">34869451</ArticleId></ArticleIdList></Reference><Reference><Citation>Kritas S.K., et al. Mast cells contribute to coronavirus-induced inflammation: new anti-inflammatory strategy. J. Biol. Regul. Homeost. Agents. 2020;34:9&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">32013309</ArticleId></ArticleIdList></Reference><Reference><Citation>Afrin L.B., et al. Mast cell activation disease: An underappreciated cause of neurologic and psychiatric symptoms and diseases. Brain Behav. Immun. 2015;50:314&#x2013;321.</Citation><ArticleIdList><ArticleId IdType="pubmed">26162709</ArticleId></ArticleIdList></Reference><Reference><Citation>Maxwell A.J., et al. Identification of key signaling pathways induced by SARS-CoV2 that underlie thrombosis and vascular injury in COVID-19 patients. J. Leukoc. Biol. 2021;109:35&#x2013;47.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7753679</ArticleId><ArticleId IdType="pubmed">33242368</ArticleId></ArticleIdList></Reference><Reference><Citation>Vojdani A., et al. Reaction of human monoclonal antibodies to SARS-CoV-2 proteins with tissue antigens: implications for autoimmune diseases. Front. Immunol. 2020;11</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7873987</ArticleId><ArticleId IdType="pubmed">33584709</ArticleId></ArticleIdList></Reference><Reference><Citation>Jarrott B., et al. &#x2018;LONG COVID&#x2019;-a hypothesis for understanding the biological basis and pharmacological treatment strategy. Pharmacol. Res. Perspect. 2022;10</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8929332</ArticleId><ArticleId IdType="pubmed">35029046</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan D.X., Reiter R.J. Mechanisms and clinical evidence to support melatonin's use in severe COVID-19 patients to lower mortality. Life Sci. 2022;294</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8800937</ArticleId><ArticleId IdType="pubmed">35108568</ArticleId></ArticleIdList></Reference><Reference><Citation>Kell D.B. Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases. BMC Med. Genet. 2009;2:2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2672098</ArticleId><ArticleId IdType="pubmed">19133145</ArticleId></ArticleIdList></Reference><Reference><Citation>Cross K.M., et al. Melatonin for the early treatment of COVID-19: a narrative review of current evidence and possible efficacy. Endocr. Pract. 2021;27:850&#x2013;855.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8190272</ArticleId><ArticleId IdType="pubmed">34119679</ArticleId></ArticleIdList></Reference><Reference><Citation>Gavrilova N., et al. New clinical phenotype of the post-covid syndrome: fibromyalgia and joint hypermobility condition. Pathophysiology. 2022;29:24&#x2013;29.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8954589</ArticleId><ArticleId IdType="pubmed">35366287</ArticleId></ArticleIdList></Reference><Reference><Citation>Yong S.J. Long COVID or post-COVID-19 syndrome: putative pathophysiology, risk factors, and treatments. Infect. Dis. (Lond) 2021;53:737&#x2013;754.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8146298</ArticleId><ArticleId IdType="pubmed">34024217</ArticleId></ArticleIdList></Reference><Reference><Citation>Jarrahi A., et al. Neurological consequences of COVID-19: what have we learned and where do we go from here? J. Neuroinflammation. 2020;17:286.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7525232</ArticleId><ArticleId IdType="pubmed">32998763</ArticleId></ArticleIdList></Reference><Reference><Citation>Helms J., et al. Cardiac injury in COVID-19. Intensive Care Med. 2022;48:111&#x2013;113.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8562019</ArticleId><ArticleId IdType="pubmed">34727214</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang C., et al. Liver injury in COVID-19: management and challenges. Lancet Gastroenterol. Hepatol. 2020;5:428&#x2013;430.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7129165</ArticleId><ArticleId IdType="pubmed">32145190</ArticleId></ArticleIdList></Reference><Reference><Citation>Heiss R., et al. Pulmonary dysfunction after pediatric COVID-19. Radiology. 2022;306</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9513839</ArticleId><ArticleId IdType="pubmed">36125379</ArticleId></ArticleIdList></Reference><Reference><Citation>Grist J.T., et al. Lung abnormalities detected with hyperpolarized (129)Xe MRI in patients with Long COVID. Radiology. 2022;305:709&#x2013;717.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9134268</ArticleId><ArticleId IdType="pubmed">35608443</ArticleId></ArticleIdList></Reference><Reference><Citation>Lloyd-Jones G., et al. The COVID-19 pathway: a proposed oral-vascular-pulmonary route of SARS-CoV-2 infection and the importance of oral healthcare measures. J. Oral Med. Dental Res. 2021;2:1&#x2013;25.</Citation></Reference><Reference><Citation>van Haren F.M.P., et al. Nebulised heparin as a treatment for COVID-19: scientific rationale and a call for randomised evidence. Crit. Care. 2020;24:454.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7374660</ArticleId><ArticleId IdType="pubmed">32698853</ArticleId></ArticleIdList></Reference><Reference><Citation>Wichmann D., et al. Autopsy findings and venous thromboembolism in patients with COVID-19: a prospective cohort study. Ann. Intern. Med. 2020;173:268&#x2013;277.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7240772</ArticleId><ArticleId IdType="pubmed">32374815</ArticleId></ArticleIdList></Reference><Reference><Citation>Ostergaard L. SARS CoV-2 related microvascular damage and symptoms during and after COVID-19: Consequences of capillary transit-time changes, tissue hypoxia and inflammation. Physiol. Rep. 2021;9</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7849453</ArticleId><ArticleId IdType="pubmed">33523608</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang C., et al. Long COVID: the nature of thrombotic sequelae determines the necessity of early anticoagulation. Front. Cell. Infect. Microbiol. 2022;12</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9016198</ArticleId><ArticleId IdType="pubmed">35449732</ArticleId></ArticleIdList></Reference><Reference><Citation>Moasefi N., et al. How could perfluorocarbon affect cytokine storm and angiogenesis in coronavirus disease 2019 (COVID-19): role of hypoxia-inducible factor 1alpha. Inflamm. Res. 2021;70:749&#x2013;752.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8233630</ArticleId><ArticleId IdType="pubmed">34173853</ArticleId></ArticleIdList></Reference><Reference><Citation>Fox S.E., et al. Unexpected features of cardiac pathology in COVID-19 infection. Circulation. 2020;142:1123&#x2013;1125.</Citation><ArticleIdList><ArticleId IdType="pubmed">32689809</ArticleId></ArticleIdList></Reference><Reference><Citation>Paniz-Mondolfi A., et al. Central nervous system involvement by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) J. Med. Virol. 2020;92:699&#x2013;702.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7264598</ArticleId><ArticleId IdType="pubmed">32314810</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris A.G., Skalak T.C. Effects of leukocyte activation on capillary hemodynamics in skeletal muscle. Am. J. Phys. 1993;264:H909&#x2013;H916.</Citation><ArticleIdList><ArticleId IdType="pubmed">8456992</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruz Hernandez J.C., et al. Neutrophil adhesion in brain capillaries reduces cortical blood flow and impairs memory function in Alzheimer's disease mouse models. Nat. Neurosci. 2019;22:413&#x2013;420.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6508667</ArticleId><ArticleId IdType="pubmed">30742116</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryan F.J., et al. Long-term perturbation of the peripheral immune system months after SARS-CoV-2 infection. BMC Med. 2022;20:26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8758383</ArticleId><ArticleId IdType="pubmed">35027067</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang D., et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020;323:1061&#x2013;1069.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7042881</ArticleId><ArticleId IdType="pubmed">32031570</ArticleId></ArticleIdList></Reference><Reference><Citation>Kell D.B., Pretorius E. The potential role of ischaemia-reperfusion injury in chronic, relapsing diseases such as rheumatoid arthritis, Long COVID, and ME/CFS: evidence, mechanisms, and therapeutic implications. Biomed. J. 2022;479:1653&#x2013;1708.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9484810</ArticleId><ArticleId IdType="pubmed">36043493</ArticleId></ArticleIdList></Reference><Reference><Citation>Chouchani E.T., et al. Ischaemic accumulation of succinate controls reperfusion injury through mitochondrial ROS. Nature. 2014;515:431&#x2013;435.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4255242</ArticleId><ArticleId IdType="pubmed">25383517</ArticleId></ArticleIdList></Reference><Reference><Citation>Granger D.N., Kvietys P.R. Reperfusion injury and reactive oxygen species: The evolution of a concept. Redox Biol. 2015;6:524&#x2013;551.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4625011</ArticleId><ArticleId IdType="pubmed">26484802</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaeschke H., Woolbright B.L. Current strategies to minimize hepatic ischemia-reperfusion injury by targeting reactive oxygen species. Transplant. Rev. (Orlando) 2012;26:103&#x2013;114.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3575198</ArticleId><ArticleId IdType="pubmed">22459037</ArticleId></ArticleIdList></Reference><Reference><Citation>Ren G., et al. Inflammatory mechanisms in myocardial infarction. Curr. Drug Targets Inflamm. Allergy. 2003;2:242&#x2013;256.</Citation><ArticleIdList><ArticleId IdType="pubmed">14561159</ArticleId></ArticleIdList></Reference><Reference><Citation>Oliynyk O.V., et al. Oxygen metabolism markers as predictors of mortality in severe COVID-19. Int. J. Infect. Dis. 2021;103:452&#x2013;456.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7833681</ArticleId><ArticleId IdType="pubmed">33310024</ArticleId></ArticleIdList></Reference><Reference><Citation>Santinelli L., et al. Oral bacteriotherapy reduces the occurrence of chronic fatigue in COVID-19 patients. Front. Nutr. 2021;8</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8790565</ArticleId><ArticleId IdType="pubmed">35096923</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalbandian A., et al. Post-acute COVID-19 syndrome. Nat. Med. 2021;27:601&#x2013;615.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8893149</ArticleId><ArticleId IdType="pubmed">33753937</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen Z., et al. Genomic diversity of severe acute respiratory syndrome-coronavirus 2 in patients with Coronavirus disease 2019. Clin. Infect. Dis. 2020;71:713&#x2013;720.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7108196</ArticleId><ArticleId IdType="pubmed">32129843</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuo T., et al. Alterations in gut microbiota of patients with COVID-19 during time of hospitalization. Gastroenterology. 2020;159:944&#x2013;955.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7237927</ArticleId><ArticleId IdType="pubmed">32442562</ArticleId></ArticleIdList></Reference><Reference><Citation>Proal A.D., et al. Microbe-microbe and host-microbe interactions drive microbiome dysbiosis and inflammatory processes. Discov. Med. 2017;23:51&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">28245427</ArticleId></ArticleIdList></Reference><Reference><Citation>Shin W., Kim H.J. Intestinal barrier dysfunction orchestrates the onset of inflammatory host-microbiome cross-talk in a human gut inflammation-on-a-chip. Proc. Natl. Acad. Sci. U. S. A. 2018;115:E10539&#x2013;E10547.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6233106</ArticleId><ArticleId IdType="pubmed">30348765</ArticleId></ArticleIdList></Reference><Reference><Citation>Blitshteyn S., Whitelaw S. Postural orthostatic tachycardia syndrome (POTS) and other autonomic disorders after COVID-19 infection: a case series of 20 patients. Immunol. Res. 2021;69:205&#x2013;211.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8009458</ArticleId><ArticleId IdType="pubmed">33786700</ArticleId></ArticleIdList></Reference><Reference><Citation>Bisaccia G., et al. Post-acute sequelae of COVID-19 and cardiovascular autonomic dysfunction: what do we know? J. Cardiovasc. Dev. Dis. 2021;8:156.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8621226</ArticleId><ArticleId IdType="pubmed">34821709</ArticleId></ArticleIdList></Reference><Reference><Citation>Aranyo J., et al. Inappropriate sinus tachycardia in post-COVID-19 syndrome. Sci. Rep. 2022;12:298.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8741896</ArticleId><ArticleId IdType="pubmed">34996973</ArticleId></ArticleIdList></Reference><Reference><Citation>Ladlow P., et al. Dysautonomia following COVID-19 is not associated with subjective limitations or symptoms but is associated with objective functional limitations. Heart Rhythm. 2022;19:613&#x2013;620.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8656177</ArticleId><ArticleId IdType="pubmed">34896622</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez-Leon S., et al. More than 50 long-term effects of COVID-19: a systematic review and meta-analysis. Sci. Rep. 2021;11:16144.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8352980</ArticleId><ArticleId IdType="pubmed">34373540</ArticleId></ArticleIdList></Reference><Reference><Citation>Barizien N., et al. Clinical characterization of dysautonomia in long COVID-19 patients. Sci. Rep. 2021;11:1&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8263555</ArticleId><ArticleId IdType="pubmed">34234251</ArticleId></ArticleIdList></Reference><Reference><Citation>Vernino S., et al. Postural orthostatic tachycardia syndrome (POTS): State of the science and clinical care from a 2019 National Institutes of Health Expert Consensus Meeting - Part 1. Auton. Neurosci. 2021;235</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8455420</ArticleId><ArticleId IdType="pubmed">34144933</ArticleId></ArticleIdList></Reference><Reference><Citation>Stewart J.M., Montgomery L.D. Regional blood volume and peripheral blood flow in postural tachycardia syndrome. Am. J. Physiol. Heart Circ. Physiol. 2004;287:H1319&#x2013;H1327.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4515760</ArticleId><ArticleId IdType="pubmed">15117717</ArticleId></ArticleIdList></Reference><Reference><Citation>Novak P., et al. Multisystem Involvement in post-acute sequelae of Coronavirus disease 19. Ann. Neurol. 2022;91:367&#x2013;379.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9011495</ArticleId><ArticleId IdType="pubmed">34952975</ArticleId></ArticleIdList></Reference><Reference><Citation>Campen C., et al. Cerebral blood flow is reduced in ME/CFS during head-up tilt testing even in the absence of hypotension or tachycardia: a quantitative, controlled study using Doppler echography. Clin. Neurophysiol. Pract. 2020;5:50&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7044650</ArticleId><ArticleId IdType="pubmed">32140630</ArticleId></ArticleIdList></Reference><Reference><Citation>Campen C., et al. Reductions in cerebral blood flow can be provoked by sitting in severe myalgic encephalomyelitis/chronic fatigue syndrome patients. Healthcare (Basel) 2020;8:394.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7712289</ArticleId><ArticleId IdType="pubmed">33050553</ArticleId></ArticleIdList></Reference><Reference><Citation>van Campen C.M.C., et al. Cerebral blood flow is reduced in severe myalgic encephalomyelitis/chronic fatigue syndrome patients during mild orthostatic stress testing: an exploratory study at 20 degrees of head-up tilt testing. Healthcare. 2020;8:169.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7349207</ArticleId><ArticleId IdType="pubmed">32545797</ArticleId></ArticleIdList></Reference><Reference><Citation>Louapre C., et al. Clinical characteristics and outcomes in patients with Coronavirus disease 2019 and multiple sclerosis. JAMA Neurol. 2020;77:1079&#x2013;1088.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7320356</ArticleId><ArticleId IdType="pubmed">32589189</ArticleId></ArticleIdList></Reference><Reference><Citation>Novak P. Post COVID-19 syndrome associated with orthostatic cerebral hypoperfusion syndrome, small fiber neuropathy and benefit of immunotherapy: a case report. eNeurologicalSci. 2020;21</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7502253</ArticleId><ArticleId IdType="pubmed">32984564</ArticleId></ArticleIdList></Reference><Reference><Citation>Oaklander A.L., et al. Peripheral neuropathy evaluations of patients with prolonged Long COVID. Neurol Neuroimmunol. Neuroinflamm. 2022;9</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8889896</ArticleId><ArticleId IdType="pubmed">35232750</ArticleId></ArticleIdList></Reference><Reference><Citation>Abrams R.M.C., et al. Small fiber neuropathy associated with SARS-CoV-2 infection. Muscle Nerve. 2022;65:440&#x2013;443.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8661991</ArticleId><ArticleId IdType="pubmed">34766365</ArticleId></ArticleIdList></Reference><Reference><Citation>Guilmot A., et al. Immune-mediated neurological syndromes in SARS-CoV-2-infected patients. J. Neurol. 2021;268:751&#x2013;757.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7391231</ArticleId><ArticleId IdType="pubmed">32734353</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruzieh M., et al. The role of autoantibodies in the syndromes of orthostatic intolerance: a systematic review. Scand. Cardiovasc. J. 2017;51:243&#x2013;247.</Citation><ArticleIdList><ArticleId IdType="pubmed">28738696</ArticleId></ArticleIdList></Reference><Reference><Citation>Li H., et al. Agonistic autoantibodies as vasodilators in orthostatic hypotension: a new mechanism. Hypertension. 2012;59:402&#x2013;408.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3275920</ArticleId><ArticleId IdType="pubmed">22215709</ArticleId></ArticleIdList></Reference><Reference><Citation>Li H., et al. Autoimmune basis for postural tachycardia syndrome. J. Am. Heart Assoc. 2014;3</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3959717</ArticleId><ArticleId IdType="pubmed">24572257</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu X., et al. Autoantibody activation of beta-adrenergic and muscarinic receptors contributes to an &#x2018;autoimmune&#x2019; orthostatic hypotension. J. Am. Soc. Hypertens. 2012;6:40&#x2013;47.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3259269</ArticleId><ArticleId IdType="pubmed">22130180</ArticleId></ArticleIdList></Reference><Reference><Citation>Fedorowski A., et al. Antiadrenergic autoimmunity in postural tachycardia syndrome. Ep Europace. 2017;19:1211&#x2013;1219.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5834103</ArticleId><ArticleId IdType="pubmed">27702852</ArticleId></ArticleIdList></Reference><Reference><Citation>Stein S.R., et al. SARS-CoV-2 infection and persistence in the human body and brain at autopsy. Nature. 2022;612:758&#x2013;763.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9749650</ArticleId><ArticleId IdType="pubmed">36517603</ArticleId></ArticleIdList></Reference><Reference><Citation>Moyano A.J., et al. Vagus nerve neuropathy related to SARS COV-2 infection. IDCases. 2021;26</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8357529</ArticleId><ArticleId IdType="pubmed">34401328</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarubbo F., et al. Neurological consequences of COVID-19 and brain related pathogenic mechanisms: a new challenge for neuroscience. Brain Behav. Immun. Health. 2022;19</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8629776</ArticleId><ArticleId IdType="pubmed">34870247</ArticleId></ArticleIdList></Reference><Reference><Citation>Esmon C.T. The interactions between inflammation and coagulation. Br. J. Haematol. 2005;131:417&#x2013;430.</Citation><ArticleIdList><ArticleId IdType="pubmed">16281932</ArticleId></ArticleIdList></Reference><Reference><Citation>Szotowski B., et al. Procoagulant soluble tissue factor is released from endothelial cells in response to inflammatory cytokines. Circ. Res. 2005;96:1233&#x2013;1239.</Citation><ArticleIdList><ArticleId IdType="pubmed">15920023</ArticleId></ArticleIdList></Reference><Reference><Citation>Esmon C.T. The impact of the inflammatory response on coagulation. Thromb. Res. 2004;114:321&#x2013;327.</Citation><ArticleIdList><ArticleId IdType="pubmed">15507261</ArticleId></ArticleIdList></Reference><Reference><Citation>Levi M., van der Poll T. Two-way interactions between inflammation and coagulation. Trends Cardiovasc. Med. 2005;15:254&#x2013;259.</Citation><ArticleIdList><ArticleId IdType="pubmed">16226680</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuo Y., et al. Plasma tissue plasminogen activator and plasminogen activator inhibitor-1 in hospitalized COVID-19 patients. Sci. Rep. 2021;11:1580.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7810990</ArticleId><ArticleId IdType="pubmed">33452298</ArticleId></ArticleIdList></Reference><Reference><Citation>Fricke-Galindo I., et al. SERPINE1 rs6092 variant is related to plasma coagulation proteins in patients with severe COVID-19 from a tertiary care hospital. Biology (Basel) 2022;11:595.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9029072</ArticleId><ArticleId IdType="pubmed">35453794</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan S.S. The central role of PAI-1 in COVID-19: thrombosis and beyond. Am. J. Respir. Cell Mol. Biol. 2021;65:238&#x2013;240.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8485998</ArticleId><ArticleId IdType="pubmed">34086538</ArticleId></ArticleIdList></Reference><Reference><Citation>Visser M.J.E., et al. Thrombosis in Psoriasis: Cutaneous Cytokine Production as a Potential Driving Force of Haemostatic Dysregulation and Subsequent Cardiovascular Risk. Front. Immunol. 2021;12</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8324086</ArticleId><ArticleId IdType="pubmed">34335591</ArticleId></ArticleIdList></Reference><Reference><Citation>Camerer E., et al. Tissue factor- and factor X-dependent activation of protease-activated receptor 2 by factor VIIa. Proc. Natl. Acad. Sci. U. S. A. 2000;97:5255&#x2013;5260.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC25815</ArticleId><ArticleId IdType="pubmed">10805786</ArticleId></ArticleIdList></Reference><Reference><Citation>Camerer E., et al. Genetic evidence that protease-activated receptors mediate factor Xa signaling in endothelial cells. J. Biol. Chem. 2002;277:16081&#x2013;16087.</Citation><ArticleIdList><ArticleId IdType="pubmed">11850418</ArticleId></ArticleIdList></Reference><Reference><Citation>de Jonge E., et al. Activation of coagulation by administration of recombinant factor VIIa elicits interleukin 6 (IL-6) and IL-8 release in healthy human subjects. Clin. Diagn. Lab. Immunol. 2003;10:495&#x2013;497.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC154959</ArticleId><ArticleId IdType="pubmed">12738659</ArticleId></ArticleIdList></Reference><Reference><Citation>Vorlova S., et al. Coagulation factor XII induces pro-inflammatory cytokine responses in macrophages and promotes atherosclerosis in mice. Thromb. Haemost. 2017;117:176&#x2013;187.</Citation><ArticleIdList><ArticleId IdType="pubmed">27786338</ArticleId></ArticleIdList></Reference><Reference><Citation>Gros A., et al. Platelets in inflammation: regulation of leukocyte activities and vascular repair. Front. Immunol. 2014;5:678.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4285099</ArticleId><ArticleId IdType="pubmed">25610439</ArticleId></ArticleIdList></Reference><Reference><Citation>Mullin J.L., et al. Recombinant fibrinogen studies reveal that thrombin specificity dictates order of fibrinopeptide release. J. Biol. Chem. 2000;275:25239&#x2013;25246.</Citation><ArticleIdList><ArticleId IdType="pubmed">10837485</ArticleId></ArticleIdList></Reference><Reference><Citation>Riedel T., et al. Fibrinopeptides A and B release in the process of surface fibrin formation. Blood. 2011;117:1700&#x2013;1706.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3056594</ArticleId><ArticleId IdType="pubmed">21106983</ArticleId></ArticleIdList></Reference><Reference><Citation>Kell D.B., Pretorius E. The simultaneous occurrence of both hypercoagulability and hypofibrinolysis in blood and serum during systemic inflammation, and the roles of iron and fibrin(ogen) Integr. Biol. 2015;7:24&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">25335120</ArticleId></ArticleIdList></Reference><Reference><Citation>Kell D.B., Pretorius E. Proteins behaving badly. Substoichiometric molecular control and amplification of the initiation and nature of amyloid fibril formation: lessons from and for blood clotting. Prog. Biophys. Mol. Biol. 2017;123:16&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">27554450</ArticleId></ArticleIdList></Reference><Reference><Citation>Pretorius E., et al. Substantial fibrin amyloidogenesis in type 2 diabetes assessed using amyloid-selective fluorescent stains. Cardiovasc. Diabetol. 2017;16:141.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5668975</ArticleId><ArticleId IdType="pubmed">29096623</ArticleId></ArticleIdList></Reference><Reference><Citation>Nunes J.M., et al. The occurrence of hyperactivated platelets and fibrinaloid microclots in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) Pharmaceuticals (Basel) 2022;15:931.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9413879</ArticleId><ArticleId IdType="pubmed">36015078</ArticleId></ArticleIdList></Reference><Reference><Citation>Laubscher, G.J. et al. TEG(&#xae;), microclot and platelet mapping for guiding early management of severe COVID-19 coagulopathy. J. Clin. Med. 10, 5381</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8621180</ArticleId><ArticleId IdType="pubmed">34830660</ArticleId></ArticleIdList></Reference><Reference><Citation>Pretorius E., et al. Prevalence of readily detected amyloid blood clots in 'unclotted' type 2 diabetes mellitus and COVID-19 plasma: a preliminary report. Cardiovasc. Diabetol. 2020;19:193.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7670290</ArticleId><ArticleId IdType="pubmed">33203441</ArticleId></ArticleIdList></Reference><Reference><Citation>Charfeddine S., et al. Long COVID 19 syndrome: is it related to microcirculation and endothelial dysfunction? Insights from TUN-EndCOV study. Front. Cardiovasc. Med. 2021;8</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8670225</ArticleId><ArticleId IdType="pubmed">34917659</ArticleId></ArticleIdList></Reference><Reference><Citation>Huertas A., et al. Endothelial cell dysfunction: a major player in SARS-CoV-2 infection (COVID-19)? Eur. Respir. J. 2020;56</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7301835</ArticleId><ArticleId IdType="pubmed">32554538</ArticleId></ArticleIdList></Reference><Reference><Citation>Varga Z., et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020;395:1417&#x2013;1418.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7172722</ArticleId><ArticleId IdType="pubmed">32325026</ArticleId></ArticleIdList></Reference><Reference><Citation>Perico L., et al. Immunity, endothelial injury and complement-induced coagulopathy in COVID-19. Nat. Rev. Nephrol. 2021;17:46&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7570423</ArticleId><ArticleId IdType="pubmed">33077917</ArticleId></ArticleIdList></Reference><Reference><Citation>Teuwen L.A., et al. COVID-19: the vasculature unleashed. Nat. Rev. Immunol. 2020;20:389&#x2013;391.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7240244</ArticleId><ArticleId IdType="pubmed">32439870</ArticleId></ArticleIdList></Reference><Reference><Citation>Abeyama K., et al. The N-terminal domain of thrombomodulin sequesters high-mobility group-B1 protein, a novel antiinflammatory mechanism. J. Clin. Invest. 2005;115:1267&#x2013;1274.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1077171</ArticleId><ArticleId IdType="pubmed">15841214</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwaki T., et al. A cardioprotective role for the endothelial protein C receptor in lipopolysaccharide-induced endotoxemia in the mouse. Blood. 2005;105:2364&#x2013;2371.</Citation><ArticleIdList><ArticleId IdType="pubmed">15528312</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahamed J., Laurence J. Long COVID endotheliopathy: hypothesized mechanisms and potential therapeutic approaches. J. Clin. Invest. 2022;132</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9337829</ArticleId><ArticleId IdType="pubmed">35912863</ArticleId></ArticleIdList></Reference><Reference><Citation>MacDonald M.E., et al. Lymphatic coagulation and neutrophil extracellular traps in lung-draining lymph nodes of COVID-19 decedents. Blood Adv. 2022;6:6249&#x2013;6262.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9394105</ArticleId><ArticleId IdType="pubmed">35977099</ArticleId></ArticleIdList></Reference><Reference><Citation>Pisareva E., et al. Persistence of neutrophil extracellular traps and anticardiolipin auto-antibodies in post-acute phase COVID-19 patients. J. Med. Virol. 2023;95</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9874393</ArticleId><ArticleId IdType="pubmed">36226380</ArticleId></ArticleIdList></Reference><Reference><Citation>Wagner D.D., Frenette P.S. The vessel wall and its interactions. Blood. 2008;111:5271&#x2013;5281.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2396724</ArticleId><ArticleId IdType="pubmed">18502843</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang S., et al. SARS-CoV-2 binds platelet ACE2 to enhance thrombosis in COVID-19. J. Hematol. Oncol. 2020;13:120.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7471641</ArticleId><ArticleId IdType="pubmed">32887634</ArticleId></ArticleIdList></Reference><Reference><Citation>Yau J.W., et al. Endothelial cell control of thrombosis. BMC Cardiovasc. Disord. 2015;15:130.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4617895</ArticleId><ArticleId IdType="pubmed">26481314</ArticleId></ArticleIdList></Reference><Reference><Citation>Mast A.E. Tissue factor pathway inhibitor: multiple anticoagulant activities for a single protein. Arterioscler. Thromb. Vasc. Biol. 2016;36:9&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4690769</ArticleId><ArticleId IdType="pubmed">26603155</ArticleId></ArticleIdList></Reference><Reference><Citation>Speyer C.L., Ward P.A. Role of endothelial chemokines and their receptors during inflammation. J. Investig. Surg. 2011;24:18&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pubmed">21275526</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosell A., et al. Patients with COVID-19 have elevated levels of circulating extracellular vesicle tissue factor activity that is associated with severity and mortality-brief report. Arterioscler. Thromb. Vasc. Biol. 2021;41:878&#x2013;882.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7837685</ArticleId><ArticleId IdType="pubmed">33267656</ArticleId></ArticleIdList></Reference><Reference><Citation>Arganaraz G.A., et al. Phosphatidylserine inside out: a possible underlying mechanism in the inflammation and coagulation abnormalities of COVID-19. Cell Commun. Signal. 2020;18:190.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7765775</ArticleId><ArticleId IdType="pubmed">33357215</ArticleId></ArticleIdList></Reference><Reference><Citation>Lind S.E. Phosphatidylserine is an overlooked mediator of COVID-19 thromboinflammation. Heliyon. 2021;7</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7817455</ArticleId><ArticleId IdType="pubmed">33495740</ArticleId></ArticleIdList></Reference><Reference><Citation>Althaus K., et al. Antibody-induced procoagulant platelets in severe COVID-19 infection. Blood. 2021;137:1061&#x2013;1071.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7791311</ArticleId><ArticleId IdType="pubmed">33512415</ArticleId></ArticleIdList></Reference><Reference><Citation>Knight J.S., et al. The intersection of COVID-19 and autoimmunity. J. Clin. Invest. 2021;131</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8670833</ArticleId><ArticleId IdType="pubmed">34710063</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruiz-Arguelles G.J., et al. Natural anticoagulants in systemic lupus erythematosus. Deficiency of protein S bound to C4bp associates with recent history of venous thromboses, antiphospholipid antibodies, and the antiphospholipid syndrome. J. Rheumatol. 1991;18:552&#x2013;558.</Citation><ArticleIdList><ArticleId IdType="pubmed">1829765</ArticleId></ArticleIdList></Reference><Reference><Citation>Mineo C. Inhibition of nitric oxide and antiphospholipid antibody-mediated thrombosis. Curr. Rheumatol. Rep. 2013;15:324.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3625922</ArticleId><ArticleId IdType="pubmed">23519891</ArticleId></ArticleIdList></Reference><Reference><Citation>Krone K.A., et al. Impaired fibrinolysis in the antiphospholipid syndrome. Curr. Rheumatol. Rep. 2010;12:53&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2862601</ArticleId><ArticleId IdType="pubmed">20425534</ArticleId></ArticleIdList></Reference><Reference><Citation>Mei Z.W., et al. Role of von Willebrand Factor in COVID-19 Associated Coagulopathy. J. Appl. Lab. Med. 2021;6:1305&#x2013;1315.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8135722</ArticleId><ArticleId IdType="pubmed">33930144</ArticleId></ArticleIdList></Reference><Reference><Citation>Eltzschig H.K., Carmeliet P. Hypoxia and inflammation. N. Engl. J. Med. 2011;364:656&#x2013;665.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3930928</ArticleId><ArticleId IdType="pubmed">21323543</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng F., et al. Endothelial microvesicles in hypoxic hypoxia diseases. J. Cell. Mol. Med. 2018;22:3708&#x2013;3718.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6050493</ArticleId><ArticleId IdType="pubmed">29808945</ArticleId></ArticleIdList></Reference><Reference><Citation>Katsoularis I., et al. Risks of deep vein thrombosis, pulmonary embolism, and bleeding after covid-19: nationwide self-controlled cases series and matched cohort study. BMJ. 2022;377</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8984137</ArticleId><ArticleId IdType="pubmed">35387772</ArticleId></ArticleIdList></Reference><Reference><Citation>Jim&#xe9;nez-Rodr&#xed;guez B.M., et al. On the single and multiple associations of COVID-19 post-acute sequelae: 6-month prospective cohort study. Sci. Rep. 2022;12:3402.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8888754</ArticleId><ArticleId IdType="pubmed">35233062</ArticleId></ArticleIdList></Reference><Reference><Citation>Knight R., et al. Association of COVID-19 with major arterial and venous thrombotic diseases: a population-wide cohort study of 48 million adults in England and Wales. Circulation. 2022;146:892&#x2013;906.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9484653</ArticleId><ArticleId IdType="pubmed">36121907</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Y., et al. Long-term cardiovascular outcomes of COVID-19. Nat. Med. 2022;28:583&#x2013;590.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8938267</ArticleId><ArticleId IdType="pubmed">35132265</ArticleId></ArticleIdList></Reference><Reference><Citation>Horby P., et al. Dexamethasone in hospitalized patients with Covid-19. N. Engl. J. Med. 2021;384:693&#x2013;704.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7383595</ArticleId><ArticleId IdType="pubmed">32678530</ArticleId></ArticleIdList></Reference><Reference><Citation>Charfeddine S., et al. Sulodexide in the treatment of patients with long COVID 19 symptoms and endothelial dysfunction: the results of TUN-EndCOV study. Arch. Cardiovasc. Dis. Suppl. 2022;14:127.</Citation></Reference><Reference><Citation>Belcaro G., et al. Preventive effects of Pycnogenol&#xae; on cardiovascular risk factors (including endothelial function) and microcirculation in subjects recovering from coronavirus disease 2019 (COVID-19) Minerva Med. 2022;113:300&#x2013;308.</Citation><ArticleIdList><ArticleId IdType="pubmed">34060731</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaeger B.R., et al. The potential of heparin-induced extracorporeal LDL/fibrinogen precipitation (H.E.L.P.)-apheresis for patients with severe acute or chronic COVID-19. Front. Cardiovasc. Med. 2022;9</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9592739</ArticleId><ArticleId IdType="pubmed">36304538</ArticleId></ArticleIdList></Reference><Reference><Citation>Moerland M., et al. Evaluation of the EndoPAT as a tool to assess endothelial function. Int. J. Vasc. Med. 2012;2012</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3303545</ArticleId><ArticleId IdType="pubmed">22500237</ArticleId></ArticleIdList></Reference><Reference><Citation>Heerdt P.M., et al. Impaired systemic oxygen extraction long after mild COVID-19: potential perioperative implications. Br. J. Anaesth. 2022;128:e246&#x2013;e249.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8710396</ArticleId><ArticleId IdType="pubmed">35067364</ArticleId></ArticleIdList></Reference><Reference><Citation>Glynne P., et al. Long COVID following mild SARS-CoV-2 infection: characteristic T cell alterations and response to antihistamines. J. Investig. Med. 2022;70:61&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8494538</ArticleId><ArticleId IdType="pubmed">34611034</ArticleId></ArticleIdList></Reference><Reference><Citation>Dani M., et al. Autonomic dysfunction in 'long COVID': rationale, physiology and management strategies. Clin. Med. (Lond) 2021;21:e63&#x2013;e67.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7850225</ArticleId><ArticleId IdType="pubmed">33243837</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>